Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial
The MM5 trial aimed at demonstrating a progression-free survival (PFS) difference in continued vs. response-adapted (in case of complete response, CR) lenalidomide (LEN) maintenance therapy (MT) in newly diagnosed, transplant-eligible multiple myeloma (MM). Patients were equally randomized to receiv...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
7 February 2020
|
| In: |
Leukemia
Year: 2020, Jahrgang: 34, Heft: 7, Pages: 1853-1865 |
| ISSN: | 1476-5551 |
| DOI: | 10.1038/s41375-020-0724-1 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1038/s41375-020-0724-1 Verlag, lizenzpflichtig, Volltext: https://www.nature.com/articles/s41375-020-0724-1 
|
| Verfasserangaben: | Hartmut Goldschmidt, Elias K. Mai, Jan Dürig, Christof Scheid, Katja C. Weisel, Christina Kunz, Uta Bertsch, Thomas Hielscher, Maximilian Merz, Markus Munder, Hans-Walter Lindemann, Barbara Hügle-Dörr, Diana Tichy, Nicola Giesen, Dirk Hose, Anja Seckinger, Stefanie Huhn, Steffen Luntz, Anna Jauch, Ahmet Elmaagacli, Bernhard Rabold, Stephan Fuhrmann, Peter Brossart, Martin Goerner, Helga Bernhard, Martin Hoffmann, Jens Hillengass, Marc S. Raab, Igor W. Blau, Mathias Hänel, Hans J. Salwender for the German-speaking Myeloma Multicenter Group (GMMG) |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 176993264X | ||
| 003 | DE-627 | ||
| 005 | 20240807090118.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210909s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41375-020-0724-1 |2 doi | |
| 035 | |a (DE-627)176993264X | ||
| 035 | |a (DE-599)KXP176993264X | ||
| 035 | |a (OCoLC)1295680588 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Goldschmidt, Hartmut |d 1956- |e VerfasserIn |0 (DE-588)102258023X |0 (DE-627)717003809 |0 (DE-576)365637386 |4 aut | |
| 245 | 1 | 0 | |a Response-adapted lenalidomide maintenance in newly diagnosed myeloma |b results from the phase III GMMG-MM5 trial |c Hartmut Goldschmidt, Elias K. Mai, Jan Dürig, Christof Scheid, Katja C. Weisel, Christina Kunz, Uta Bertsch, Thomas Hielscher, Maximilian Merz, Markus Munder, Hans-Walter Lindemann, Barbara Hügle-Dörr, Diana Tichy, Nicola Giesen, Dirk Hose, Anja Seckinger, Stefanie Huhn, Steffen Luntz, Anna Jauch, Ahmet Elmaagacli, Bernhard Rabold, Stephan Fuhrmann, Peter Brossart, Martin Goerner, Helga Bernhard, Martin Hoffmann, Jens Hillengass, Marc S. Raab, Igor W. Blau, Mathias Hänel, Hans J. Salwender for the German-speaking Myeloma Multicenter Group (GMMG) |
| 264 | 1 | |c 7 February 2020 | |
| 300 | |a 13 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 09.09.2021 | ||
| 520 | |a The MM5 trial aimed at demonstrating a progression-free survival (PFS) difference in continued vs. response-adapted (in case of complete response, CR) lenalidomide (LEN) maintenance therapy (MT) in newly diagnosed, transplant-eligible multiple myeloma (MM). Patients were equally randomized to receive induction therapy with PAd (bortezomib/doxorubicin/dexamethasone) or VCD (bortezomib/cyclophosphamide/dexamethasone), high-dose melphalan and autologous blood stem cell transplantation, and LEN consolidation, followed by either LEN MT for a fixed duration of 2 years (LEN-2Y) or until achievement of CR (LEN-CR, intention-to-treat population n = 502): arms A1:PAd + LEN-2Y (n = 125), B1:PAd + LEN-CR (n = 126), A2:VCD + LEN-2Y (n = 126), B2:VCD + LEN-CR (n = 125). In the LEN-CR group (B1 + B2), n = 88/17.5% patients did not start or discontinued LEN MT due to CR. There was no PFS (p = 0.60, primary endpoint) nor overall survival (OS) (p = 0.15) difference between the four study arms. On pooled LEN MT strategies, OS (hazard ratio, hazard ratio [HR] = 1.42, p = 0.03) but not PFS (HR = 1.15, p = 0.20) was shorter in LEN-CR (B1 + B2) vs. LEN-2Y (A1 + A2) groups. PFS was shortened on landmark analyses from the start of LEN MT in patients being in CR in the LEN-CR group (LEN-CR vs. LEN-2Y, HR = 1.84, p = 0.02). OS from first progression was shortened in the LEN-CR vs. LEN-2Y group (HR = 1.60, p = 0.01). LEN MT should be applied beyond CR for at least 2 years. | ||
| 700 | 1 | |a Mai, Elias K. |d 1985- |e VerfasserIn |0 (DE-588)1049182545 |0 (DE-627)781300274 |0 (DE-576)403130999 |4 aut | |
| 700 | 1 | |a Dürig, Jan |e VerfasserIn |4 aut | |
| 700 | 1 | |a Scheid, Christoph |e VerfasserIn |0 (DE-588)1075475244 |0 (DE-627)833299670 |0 (DE-576)443494495 |4 aut | |
| 700 | 1 | |a Weisel, Katja C. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kunz, Christina |e VerfasserIn |0 (DE-588)1206902620 |0 (DE-627)1693152258 |4 aut | |
| 700 | 1 | |a Bertsch, Uta |e VerfasserIn |0 (DE-588)1026849861 |0 (DE-627)727494163 |0 (DE-576)372176224 |4 aut | |
| 700 | 1 | |a Hielscher, Thomas |e VerfasserIn |0 (DE-588)1159594791 |0 (DE-627)1022977768 |0 (DE-576)50506068X |4 aut | |
| 700 | 1 | |a Merz, Maximilian |d 1985- |e VerfasserIn |0 (DE-588)1023626950 |0 (DE-627)718419278 |0 (DE-576)367168251 |4 aut | |
| 700 | 1 | |a Munder, Markus |d 1967- |e VerfasserIn |0 (DE-588)121183610 |0 (DE-627)705288188 |0 (DE-576)292574347 |4 aut | |
| 700 | 1 | |a Lindemann, Hans-Walter |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hügle-Dörr, Barbara |e VerfasserIn |0 (DE-588)1070073628 |0 (DE-627)823265528 |0 (DE-576)429746857 |4 aut | |
| 700 | 1 | |a Tichy, Diana |e VerfasserIn |0 (DE-588)1028040873 |0 (DE-627)730210081 |0 (DE-576)375518258 |4 aut | |
| 700 | 1 | |a Giesen, Nicola |d 1983- |e VerfasserIn |0 (DE-588)141844272 |0 (DE-627)631828524 |0 (DE-576)32643657X |4 aut | |
| 700 | 1 | |a Hose, Dirk |d 1969- |e VerfasserIn |0 (DE-588)139824995 |0 (DE-627)613790308 |0 (DE-576)313431698 |4 aut | |
| 700 | 1 | |a Seckinger, Anja |d 1980- |e VerfasserIn |0 (DE-588)134177371 |0 (DE-627)562118225 |0 (DE-576)278603734 |4 aut | |
| 700 | 1 | |a Huhn, Stefanie |d 1982- |e VerfasserIn |0 (DE-588)1014984424 |0 (DE-627)705313190 |0 (DE-576)349876436 |4 aut | |
| 700 | 1 | |a Luntz, Steffen P. |d 1968- |e VerfasserIn |0 (DE-588)120890216 |0 (DE-627)70506624X |0 (DE-576)292433077 |4 aut | |
| 700 | 1 | |a Jauch, Anna |d 1959- |e VerfasserIn |0 (DE-588)1025525140 |0 (DE-627)722525362 |0 (DE-576)168357496 |4 aut | |
| 700 | 1 | |a Elmaagacli, Ahmet |e VerfasserIn |4 aut | |
| 700 | 1 | |a Rabold, Bernhard |e VerfasserIn |0 (DE-588)1240856016 |0 (DE-627)1769931635 |4 aut | |
| 700 | 1 | |a Fuhrmann, Stephan |e VerfasserIn |4 aut | |
| 700 | 1 | |a Brossart, Peter |e VerfasserIn |4 aut | |
| 700 | 1 | |a Goerner, Martin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bernhard, Helga |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hoffmann, Martin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hillengaß, Jens |d 1974- |e VerfasserIn |0 (DE-588)124918549 |0 (DE-627)368073823 |0 (DE-576)294568298 |4 aut | |
| 700 | 1 | |a Raab, Marc-Steffen |d 1973- |e VerfasserIn |0 (DE-588)124052460 |0 (DE-627)706520998 |0 (DE-576)293998027 |4 aut | |
| 700 | 1 | |a Blau, Igor-Wolfgang |d 1960- |e VerfasserIn |0 (DE-588)111826438 |0 (DE-627)566073560 |0 (DE-576)289713366 |4 aut | |
| 700 | 1 | |a Hänel, Mathias |d 1964- |e VerfasserIn |0 (DE-588)17362295X |0 (DE-627)698532414 |0 (DE-576)134465970 |4 aut | |
| 700 | 1 | |a Salwender, Hans |e VerfasserIn |0 (DE-588)1114928666 |0 (DE-627)869399993 |0 (DE-576)477578233 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Leukemia |d London : Springer Nature, 1997 |g 34(2020), 7, Seite 1853-1865 |h Online-Ressource |w (DE-627)32046699X |w (DE-600)2008023-2 |w (DE-576)094139733 |x 1476-5551 |7 nnas |a Response-adapted lenalidomide maintenance in newly diagnosed myeloma results from the phase III GMMG-MM5 trial |
| 773 | 1 | 8 | |g volume:34 |g year:2020 |g number:7 |g pages:1853-1865 |g extent:13 |a Response-adapted lenalidomide maintenance in newly diagnosed myeloma results from the phase III GMMG-MM5 trial |
| 856 | 4 | 0 | |u https://doi.org/10.1038/s41375-020-0724-1 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.nature.com/articles/s41375-020-0724-1 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20210909 | ||
| 992 | |a 20210909 | ||
| 993 | |a Article | ||
| 993 | |a Article | ||
| 994 | |a 2020 | ||
| 994 | |a 2020 | ||
| 998 | |g 124052460 |a Raab, Marc-Steffen |m 124052460:Raab, Marc-Steffen |d 910000 |d 910100 |e 910000PR124052460 |e 910100PR124052460 |k 0/910000/ |k 1/910000/910100/ |p 28 | ||
| 998 | |g 124918549 |a Hillengaß, Jens |m 124918549:Hillengaß, Jens |d 910000 |d 910100 |e 910000PH124918549 |e 910100PH124918549 |k 0/910000/ |k 1/910000/910100/ |p 27 | ||
| 998 | |g 1240856016 |a Rabold, Bernhard |m 1240856016:Rabold, Bernhard |d 910000 |d 913000 |e 910000PR1240856016 |e 913000PR1240856016 |k 0/910000/ |k 1/910000/913000/ |p 21 | ||
| 998 | |g 1025525140 |a Jauch, Anna |m 1025525140:Jauch, Anna |d 910000 |d 911500 |d 50000 |e 910000PJ1025525140 |e 911500PJ1025525140 |e 50000PJ1025525140 |k 0/910000/ |k 1/910000/911500/ |k 0/50000/ |p 19 | ||
| 998 | |g 120890216 |a Luntz, Steffen P. |m 120890216:Luntz, Steffen P. |d 910000 |d 913000 |e 910000PL120890216 |e 913000PL120890216 |k 0/910000/ |k 1/910000/913000/ |p 18 | ||
| 998 | |g 1014984424 |a Huhn, Stefanie |m 1014984424:Huhn, Stefanie |d 910000 |d 910100 |e 910000PH1014984424 |e 910100PH1014984424 |k 0/910000/ |k 1/910000/910100/ |p 17 | ||
| 998 | |g 134177371 |a Seckinger, Anja |m 134177371:Seckinger, Anja |p 16 | ||
| 998 | |g 139824995 |a Hose, Dirk |m 139824995:Hose, Dirk |d 50000 |e 50000PH139824995 |k 0/50000/ |p 15 | ||
| 998 | |g 141844272 |a Giesen, Nicola |m 141844272:Giesen, Nicola |d 910000 |d 910100 |e 910000PG141844272 |e 910100PG141844272 |k 0/910000/ |k 1/910000/910100/ |p 14 | ||
| 998 | |g 1028040873 |a Tichy, Diana |m 1028040873:Tichy, Diana |d 50000 |e 50000PT1028040873 |k 0/50000/ |p 13 | ||
| 998 | |g 1070073628 |a Hügle-Dörr, Barbara |m 1070073628:Hügle-Dörr, Barbara |d 910000 |d 913000 |e 910000PH1070073628 |e 913000PH1070073628 |k 0/910000/ |k 1/910000/913000/ |p 12 | ||
| 998 | |g 1023626950 |a Merz, Maximilian |m 1023626950:Merz, Maximilian |d 910000 |d 910100 |e 910000PM1023626950 |e 910100PM1023626950 |k 0/910000/ |k 1/910000/910100/ |p 9 | ||
| 998 | |g 1159594791 |a Hielscher, Thomas |m 1159594791:Hielscher, Thomas |d 140000 |e 140000PH1159594791 |k 0/140000/ |p 8 | ||
| 998 | |g 1026849861 |a Bertsch, Uta |m 1026849861:Bertsch, Uta |d 910000 |d 910100 |e 910000PB1026849861 |e 910100PB1026849861 |k 0/910000/ |k 1/910000/910100/ |p 7 | ||
| 998 | |g 1206902620 |a Kunz, Christina |m 1206902620:Kunz, Christina |d 50000 |e 50000PK1206902620 |k 0/50000/ |p 6 | ||
| 998 | |g 1049182545 |a Mai, Elias K. |m 1049182545:Mai, Elias K. |d 910000 |d 910100 |e 910000PM1049182545 |e 910100PM1049182545 |k 0/910000/ |k 1/910000/910100/ |p 2 | ||
| 998 | |g 102258023X |a Goldschmidt, Hartmut |m 102258023X:Goldschmidt, Hartmut |d 910000 |d 910100 |e 910000PG102258023X |e 910100PG102258023X |k 0/910000/ |k 1/910000/910100/ |p 1 |x j | ||
| 999 | |a KXP-PPN176993264X |e 3975810122 | ||
| 999 | |a KXP-PPN176993264X |e 397580940X | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"name":{"displayForm":["Hartmut Goldschmidt, Elias K. Mai, Jan Dürig, Christof Scheid, Katja C. Weisel, Christina Kunz, Uta Bertsch, Thomas Hielscher, Maximilian Merz, Markus Munder, Hans-Walter Lindemann, Barbara Hügle-Dörr, Diana Tichy, Nicola Giesen, Dirk Hose, Anja Seckinger, Stefanie Huhn, Steffen Luntz, Anna Jauch, Ahmet Elmaagacli, Bernhard Rabold, Stephan Fuhrmann, Peter Brossart, Martin Goerner, Helga Bernhard, Martin Hoffmann, Jens Hillengass, Marc S. Raab, Igor W. Blau, Mathias Hänel, Hans J. Salwender for the German-speaking Myeloma Multicenter Group (GMMG)"]},"recId":"176993264X","note":["Gesehen am 09.09.2021"],"person":[{"given":"Hartmut","display":"Goldschmidt, Hartmut","family":"Goldschmidt","role":"aut"},{"given":"Elias K.","family":"Mai","display":"Mai, Elias K.","role":"aut"},{"display":"Dürig, Jan","family":"Dürig","given":"Jan","role":"aut"},{"display":"Scheid, Christoph","family":"Scheid","given":"Christoph","role":"aut"},{"role":"aut","given":"Katja C.","display":"Weisel, Katja C.","family":"Weisel"},{"role":"aut","display":"Kunz, Christina","family":"Kunz","given":"Christina"},{"display":"Bertsch, Uta","family":"Bertsch","given":"Uta","role":"aut"},{"family":"Hielscher","display":"Hielscher, Thomas","given":"Thomas","role":"aut"},{"role":"aut","display":"Merz, Maximilian","family":"Merz","given":"Maximilian"},{"role":"aut","given":"Markus","display":"Munder, Markus","family":"Munder"},{"role":"aut","family":"Lindemann","display":"Lindemann, Hans-Walter","given":"Hans-Walter"},{"role":"aut","display":"Hügle-Dörr, Barbara","family":"Hügle-Dörr","given":"Barbara"},{"family":"Tichy","display":"Tichy, Diana","given":"Diana","role":"aut"},{"display":"Giesen, Nicola","family":"Giesen","given":"Nicola","role":"aut"},{"display":"Hose, Dirk","family":"Hose","given":"Dirk","role":"aut"},{"family":"Seckinger","display":"Seckinger, Anja","given":"Anja","role":"aut"},{"display":"Huhn, Stefanie","family":"Huhn","given":"Stefanie","role":"aut"},{"given":"Steffen P.","display":"Luntz, Steffen P.","family":"Luntz","role":"aut"},{"given":"Anna","family":"Jauch","display":"Jauch, Anna","role":"aut"},{"display":"Elmaagacli, Ahmet","family":"Elmaagacli","given":"Ahmet","role":"aut"},{"role":"aut","display":"Rabold, Bernhard","family":"Rabold","given":"Bernhard"},{"display":"Fuhrmann, Stephan","family":"Fuhrmann","given":"Stephan","role":"aut"},{"given":"Peter","family":"Brossart","display":"Brossart, Peter","role":"aut"},{"given":"Martin","display":"Goerner, Martin","family":"Goerner","role":"aut"},{"role":"aut","given":"Helga","display":"Bernhard, Helga","family":"Bernhard"},{"role":"aut","given":"Martin","family":"Hoffmann","display":"Hoffmann, Martin"},{"role":"aut","given":"Jens","family":"Hillengaß","display":"Hillengaß, Jens"},{"role":"aut","given":"Marc-Steffen","family":"Raab","display":"Raab, Marc-Steffen"},{"display":"Blau, Igor-Wolfgang","family":"Blau","given":"Igor-Wolfgang","role":"aut"},{"family":"Hänel","display":"Hänel, Mathias","given":"Mathias","role":"aut"},{"role":"aut","display":"Salwender, Hans","family":"Salwender","given":"Hans"}],"title":[{"title":"Response-adapted lenalidomide maintenance in newly diagnosed myeloma","subtitle":"results from the phase III GMMG-MM5 trial","title_sort":"Response-adapted lenalidomide maintenance in newly diagnosed myeloma"}],"physDesc":[{"extent":"13 S."}],"relHost":[{"type":{"media":"Online-Ressource","bibl":"periodical"},"id":{"eki":["32046699X"],"zdb":["2008023-2"],"issn":["1476-5551"]},"language":["eng"],"origin":[{"dateIssuedKey":"1997","publisher":"Springer Nature ; Stockton Press ; Nature Publ. Group","publisherPlace":"London ; Basingstoke [u.a.] ; Basingstoke","dateIssuedDisp":"1997-"}],"part":{"volume":"34","pages":"1853-1865","text":"34(2020), 7, Seite 1853-1865","year":"2020","extent":"13","issue":"7"},"title":[{"subtitle":"normal and malignant hemopoiesis ; a peer-reviewed journal","title":"Leukemia","title_sort":"Leukemia"}],"physDesc":[{"extent":"Online-Ressource"}],"disp":"Response-adapted lenalidomide maintenance in newly diagnosed myeloma results from the phase III GMMG-MM5 trialLeukemia","pubHistory":["Nachgewiesen 11.1997 -"],"note":["Gesehen am 15.03.04"],"recId":"32046699X"}],"origin":[{"dateIssuedDisp":"7 February 2020","dateIssuedKey":"2020"}],"language":["eng"],"id":{"doi":["10.1038/s41375-020-0724-1"],"eki":["176993264X"]},"type":{"bibl":"article-journal","media":"Online-Ressource"}} | ||
| SRT | |a GOLDSCHMIDRESPONSEAD7202 | ||